GLP1R and atrial fibrillation: Acknowledgement of this effect on the heart rate led to concerns that GLP-1 receptor agonists may be associated with a higher risk for AF, especially after a pooled analysis of the phase 2b and phase 3 trials in the Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes) program with albiglutide showed a statistically significant increase in the AF incidence with this drug [50].